PD-L1 Ligand Archives

NSCLC Drug Improves Progression-Free Survival in Late-Stage Trial

Chemotherapy, Clinical Trial Endpoints, Clinical Trials, Monoclonal Antibodies, Non-Small Cell Lung Cancer (NSCLC), PD-1 Inhibitors, PD-L1 Ligand, PD-L2 Ligand, Primary Endpoints, Progression-Free Survival (PFS), R&D

Junshi Biosciences announced that the Phase III clinical trial the Chinese pharmaceutical company is conducting alongside California-based Coherus BioSciences on a potential non-small cell lung cancer (NSCLC) drug is showing positive preliminary results.

August 19, 2021/by Andrew Humphreys

FDA Approves Expanded Label for Keytruda

Approvals, FDA, FDA/Regulatory, Genetics, Label Expansion, Monoclonal Antibodies, PD-1 Inhibitors, PD-L1 Ligand, PD-L2 Ligand, Tumors

The U.S. FDA approved an expanded label for Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

April 11, 2019/by Business Wire